Edition:
United Kingdom

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

84.50DKK
3:59pm GMT
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
kr.84.50
Open
kr.84.00
Day's High
kr.85.50
Day's Low
kr.84.00
Volume
32,133
Avg. Vol
119,714
52-wk High
kr.141.00
52-wk Low
kr.82.00

Summary

Name Age Since Current Position

Alf Nicklasson

62 2015 Independent Chairman of the Board

Britt Meelby Jensen

44 2015 President, Chief Executive Officer, Member of the Executive Management

Rosemary Crane

57 2015 Independent Vice Chairman of the Board

Mats Blom

52 2016 Chief Financial Officer, Senior Vice President, Member of the Executive Management

Andrew Parker

52 2016 Senior Vice President, Chief Scientific Officer

Adam Steensberg

43 2015 Senior Vice President, Chief Medical and Development Officer

Helle Haxgart

2017 Director, Employee Representative

Hanne Heidenheim Bak

64 2016 Director, Employee Representative

Jens Stenvang

63 2014 Director, Employee Representative

Catherine Moukheibir

58 2015 Independent Director

Alain Munoz

68 2007 Independent Director

Michael Owen

66 2012 Independent Director

Biographies

Name Description

Alf Nicklasson

Dr. Alf Gunnar Martin (Martin) Nicklasson, Ph.D. has been Independent Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Martin has held broad-based executive experience from positions in European pharmaceutical and biotech companies. He held executive vice president positions at AstraZeneca PLC and has served as President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB. Prior to this he held a number of leadership positions at AB Astra and Kabi Pharmacia AB. Martin Nicklasson is chairman of the board of Orexo AB and Farma Investment A/S, as well as Board Member of Basilea Pharmaceutica Ltd., BioInvent International AB and Biocrine AB. He is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from the Uppsala University, where he is Associate Professor at the Department of Pharmaceutics.

Britt Meelby Jensen

Ms. Britt Meelby Jensen has been appointed President and Chief Executive Officer and Member of the Executive Management of Zealand Pharma A/S, effective as of January 15, 2015. Prior to joining Zealand, she headed the world leading Agilent-owned Danish diagnostics company, Dako, as the company’s CEO. Britt has extensive experience from a range of managerial positions within the life science industry, including 11 years of international experience with Novo Nordisk. At Novo Nordisk, she held various global leadership positions, including head of Diabetes Marketing Nordic, Global Diabetes Lifecycle Management, prelaunch commercial projects and more recently Corporate Vice President for Global Marketing, Market Access and Commercial Excellence. Previously, Britt has worked for McKinsey and Company and within the EU Institutions in Brussels. She holds a M.Sc. from Copenhagen Business School, Denmark and an MBA from Solvay Business School in Brussels, Belgium.

Rosemary Crane

Ms. Rosemary A. Crane has been Independent Vice Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Ms. Rosemary Crane has been CEO of Mela Sciences (2013-2014) and Epocrates (2008-2011), besides having held a number of leading positions in Johnson & Johnson and BMS. She is Member of the Board of Teva Pharmaceuticals Industries Ltd. and Unilife. Rose has a BA in Communication from the State University of New York, MBA from Kent State University.

Mats Blom

Mr. Mats Peter Blom has been Senior Vice President, Chief Financial Officer and Member of the Executive Management at Zealand Pharma A/S since January 3, 2011. Before that, he has been Vice President and CFO of the Company since March 1, 2010. He served as CFO at Swedish Orphan International a leading European orphan drug company. He has extensive managerial experience and has held CFO positions at Active Biotech and Anoto both publicly listed on Nasdaq Stockholm. Previously, Mats worked for several years as a management consultant at Gemini Consulting and at Ernst & Young’s Transaction Services division. He holds a BA in Business Administration and Economics from the University of Lund followed by an MBA from IESE University of Navarra, Barcelona. Mats is Chairman of the Board for Medical Need AB.

Andrew Parker

Mr. Andrew Parker has been appointed Senior Vice President and Chief Scientific Officer of Zealand Pharma A/S effective as of July 1, 2016. He comes from a position as General Partner and Scientific Director for the Life Sciences Investment Fund Eclosion2 & Cie SCPC in Switzerland. In parallel, he has held the position as CEO for Arisgen SA (an Eclosion2 portfolio company developing an oral peptide drug delivery technology). Andrew has more than twenty years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca to mention a few. He holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 scientific articles in renowned international journals.

Adam Steensberg

Mr. Adam Steensberg has been Senior Vice President and Chief Medical and Development Officer at Zealand Pharma A/S since March 19, 2015. Mr. Adam Steensberg joined Zealand in 2010 as Head of Clinical Development. Since 2011 he has been leading all development activities. Prior to joining Zealand, Adam has led several clinical research teams as medical director at Novo Nordisk A/S, and he has experience as clinician from the University hospital of Copenhagen. He has served as medical and scientific advisor within endocrinology, cardiology, gastroenterology, and rheumatology. He has significant experience with leading regulatory strategies and has been instrumental in implementing a patient-centric discovery and development process at Zealand. Adam has published more than 45 peer-reviewed scientific papers in international journals. Adam holds a Doctor of medicine followed by a Doctor of Medical Sciences (DMSc/ dr.med) from the University of Copenhagen, Denmark and an MBA from IMD, Switzerland.

Helle Haxgart

Ms. Helle Haxgart has been Director, Employee Representative at ZEALAND PHARMA A/S since December 1, 2017. She is Accountant within Zealand.

Hanne Heidenheim Bak

Ms. Hanne Heidenheim Bak has been appointed Director, Employee Representative at Zealand Pharma A/S, effective as of April 19, 2016. She previously held that position at the Company from April 17, 2012 to April 29, 2014. She is Senior Project Director at the Company and R&D Operations Manager at Zealand, and she holds a M.Sc. (Pharm) from the Danish University of Pharmaceutical Sciences. Prior to joining Zealand in 2006, Hanne H. Bak worked 8 years as Project Manager of late-phase development programs at H. Lundbeck A/S, followed by 9 years as Executive Director at the Lundbeck Institute.

Jens Stenvang

Mr. Jens Peter Stenvang has been appointed Employee Representative on the Board of Directors of Zealand Pharma A/S, effective as of April 29, 2014. He holds a degree as laboratory technician in Biology. He has worked with cancer and diabetes research at leading universities including UC-Berkeley, California. Before joining Zealand in October 2010, Jens Peter worked for DAKO and Beckman Coulter as global Flow Cytometry support. Jens Peter has been member of the board of Dansk Selskab for Flowcytometri since 1990, excluding a short break from 2010-2012.

Catherine Moukheibir

Ms. Catherine Moukheibir has been Independent Director of Zealand Pharma A/S since April 21, 2015. Ms. Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy at various stages of a biotech’s development, and she is currently a Member of the Board of Ablynx NV and Cerenis Therapeutics Holding SA, as well as Chairman of the Board of MedDay Pharmaceuticals S.A. and Member of the Advisory Board of Imperial College Business School. Ms. Catherine Moukheibir holds an MBA from Yale University.

Alain Munoz

Dr. Alain Munoz has been Independent Member of the Board of Directors at Zealand Pharma A/S since 2007. He served as Director of the Company from 2005 until 2006 when he resigned. Alain Munoz is CEO and founder of Amistad Pharma S.A.S. and Science, Business and Management SARL, and has over 20 years of experience in the pharmaceutical industry at senior management level. Within the Sanofi Group he served as SVP for International development and in Fournier Laboratories as SVP for the Pharmaceutical division. He is Chairman of the Board of Hybrigenics SA and member of the Board of Valneva SE. Moreover, he is adviser to Kurma Biofund. Alain Munoz holds an MD in Cardiology and Anaesthesiology from the Hospital Pitie-Salpetriere, Paris. He has numerous publications and has been a member of the scientific committee of the French Drug Agency (ANSM).

Michael Owen

Dr. Michael John Owen has been Independent Director at Zealand Pharma A/S since 2012. Michael J. Owen is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of biopharmaceuticals research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on the immune system. He has more than 150 publications and membership of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. He is Member of the board of Blink Biomedical SAS, Ossianix Inc., Avacta Group plc, GammaDelta Therapeutics and ReNeuron Group plc. Moreover, he is advisor to Kymab Ltd and CRT Pioneer Fund LP. He holds Doctorate in Philosophy degree in Biochemistry (Amino and Acid Transport in Trypanosomes) from Cambridge University and Bachelor of Arts degree in Biochemistry from Keble College, Oxford University.

Basic Compensation